Difference between revisions of "Kaye SB, et al. Clin. Cancer Res. (2012) cited as Ref 610 in DOI: 10.1038/s41392-020-0110-5 (Q9873)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 18, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English) | ||
| Property / title: A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Kaye SB, et al. Clin. Cancer Res. (2012) cited as Ref 610 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Kaye SB
0 references
2012
0 references
Clin. Cancer Res.
0 references
18
0 references
A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English)
0 references
